ENTA vs. EPIX, NLTX, AVIR, VTYX, MREO, PGEN, URGN, RANI, TERN, and INZY
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include ESSA Pharma (EPIX), Neoleukin Therapeutics (NLTX), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Mereo BioPharma Group (MREO), Precigen (PGEN), UroGen Pharma (URGN), Rani Therapeutics (RANI), Terns Pharmaceuticals (TERN), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical preparations" industry.
ESSA Pharma (NASDAQ:EPIX) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.
ESSA Pharma has a net margin of 0.00% compared to ESSA Pharma's net margin of -187.77%. Enanta Pharmaceuticals' return on equity of -17.41% beat ESSA Pharma's return on equity.
ESSA Pharma received 40 more outperform votes than Enanta Pharmaceuticals when rated by MarketBeat users. Likewise, 76.32% of users gave ESSA Pharma an outperform vote while only 56.41% of users gave Enanta Pharmaceuticals an outperform vote.
ESSA Pharma has higher earnings, but lower revenue than Enanta Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
75.1% of ESSA Pharma shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 14.7% of ESSA Pharma shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than ESSA Pharma. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 1.02 beat Enanta Pharmaceuticals' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
ESSA Pharma has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
ESSA Pharma presently has a consensus price target of $16.50, indicating a potential upside of 160.66%. Enanta Pharmaceuticals has a consensus price target of $19.33, indicating a potential upside of 53.68%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe ESSA Pharma is more favorable than Enanta Pharmaceuticals.
Summary
ESSA Pharma beats Enanta Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
